HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced
that Nancy Pecota, Aradigm's Chief Financial Officer, will present an
overview of the Company at the Stifel 2016 Healthcare Conference at the
Lotte New York Palace Hotel in New York, New York on Wednesday, November
16, 2016 at 1:30 pm Eastern Time.
A live webcast of the presentation will be available at www.aradigm.com
and a webcast replay will be archived on the Company's website for 30
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm is currently in Phase
3 development of Pulmaquin® (an investigational proprietary formulation
of ciprofloxacin for inhalation) for the treatment of non-cystic
fibrosis bronchiectasis. Aradigm's inhaled ciprofloxacin formulations
are also product candidates for treatment of patients with cystic
fibrosis and non-tuberculous mycobacteria, and for the prevention and
treatment of high threat and bioterrorism infections, such as inhaled
tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More information about Aradigm can be found at www.aradigm.com.
Aradigm, Pulmaquin and the Aradigm Logo are registered trademarks of
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005216/en/
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media